Diamond Biofund (TWSE:6901) - Stock Price, News & Analysis

6901 Stock Overview

A venture capital firm specializing in evergreen funds. More details

6901 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Risk Analysis

Earnings have declined by 56% per year over past 5 years

Makes less than USD$1m in revenue (NT$-1B)

Diamond Biofund Inc. Competitors

ABICO Asia Capital

TPEX:7777

NT$3.2b

Yuanta Futures

TPEX:6023

NT$26.1b

China Bills Finance

TWSE:2820

NT$20.1b

President Securities

TWSE:2855

NT$39.2b

Price History & Performance

Summary of all time highs, changes and price drops for Diamond Biofund
Historical stock prices
Current Share Price	NT$31.80
52 Week High	NT$53.50
52 Week Low	NT$31.10
Beta	1.58
11 Month Change	-17.19%
3 Month Change	-18.98%
1 Year Change	-36.65%
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	-84.11%

Recent updates

Shareholder Returns

	6901	TW Capital Markets	TW Market
7D	-11.3%	-2.1%	-3.4%
1Y	-36.7%	17.2%	30.2%

Return vs Industry: 6901 underperformed the TW Capital Markets industry which returned 17.2% over the past year.

Return vs Market: 6901 underperformed the TW Market which returned 30.2% over the past year.

Price Volatility

Is 6901's price volatile compared to industry and market?
6901 volatility
6901 Average Weekly Movement	4.4%
Capital Markets Industry Average Movement	2.6%
Market Average Movement	4.6%
10% most volatile stocks in TW Market	8.0%
10% least volatile stocks in TW Market	2.1%

Stable Share Price: 6901 has not had significant price volatility in the past 3 months compared to the TW market.

Volatility Over Time: 6901's weekly volatility (4%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2013	28	Yolanda Wu	www.diamondbiofund.com/tc/index.htm

Diamond Biofund Inc. is a venture capital firm specializing in evergreen funds. The firm seeks investment in start-ups and early ventures. It typically invests in biotechnology and medical investments, including new drug R&D, high-end medical equipment, innovative medical services and channels, and agricultural biotechnology.

Diamond Biofund Inc. Fundamentals Summary

How do Diamond Biofund's earnings and revenue compare to its market cap?
6901 fundamental statistics
Market cap	NT$27.04b
Earnings (TTM)	-NT$1.56b
Revenue (TTM)	n/a

-19.2x

P/S Ratio

-17.3x

P/E Ratio

Is 6901 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
6901 income statement (TTM)
Revenue	-NT$1.41b
Cost of Revenue	NT$0
Gross Profit	-NT$1.41b
Other Expenses	NT$154.36m
Earnings	-NT$1.56b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-1.84
Gross Margin	100.00%
Net Profit Margin	110.97%
Debt/Equity Ratio	0%

How did 6901 perform over the long term?

See historical performance and comparison

Diamond Biofund TWSE:6901 Stock Report